IGFBP2 and colorectal carcinoma: Network pharmacology analysis clarified a potential mechanism underlying the role of SJZD in the CRC TME and indicated that HSPB1, SPP1, IGFBP2 and TGFB1 could be potential therapeutic targets in the CRC TME.